Significance of interleukin-13 receptor alpha 2–targeted glioblastoma therapy

摘要: Glioblastoma multiforme (GBM) remains one of the most lethal primary brain tumors despite surgical and therapeutic advancements. Targeted therapies neoplastic diseases, including GBM, have received a great deal interest in recent years. A highly studied target GBM is interleukin-13 receptor α chain variant 2 (IL13Rα2). against IL13Rα2 include fusion chimera proteins IL-13 bacterial toxins, nanoparticles, oncolytic viruses. In addition, immunotherapies been developed using monoclonal antibodies cell-based strategies such as IL13Rα2-pulsed dendritic cells IL13Rα2-targeted chimeric antigen receptor–modified T cells. Advanced development has led to completion phase I clinical trials for III IL-13–conjugated toxin, with promising outcomes. Selective expression on tumor cells, while absent surrounding normal tissue, motivated continued study an important candidate targeted glioma therapy. Here, we review preclinical studies targeting discuss new advances applications.